Ex parte BORCHERDING et al. - Page 2






                     Appeal No. 1998-2088                                                                                                          
                     Application 08/372,712                                                                                                        


                     Examiner’s Answer (Id., page 7).2,3  Thus, claims 17-21 are before us for review in                                           

                     this appeal.                                                                                                                  

                              Claim 18 is representative and is reproduced below:                                                                  

                              18.     A method of inhibiting the TNF-a activity in a patient in need thereof                                       
                                      comprising administering to said patient an effective antiinflammatory                                       
                                      amount of a compound of claims 1 or 2.                                                                       

                              The examiner has not relied upon any references.                                                                     

                              This merits panel relies on the following references, already made of record                                         

                     in the PTO-892 attachment to Paper No.17, mailed 31 October 1995:                                                             

                     Fisher et al. (Fisher), “Influence of an anti-tumor necrosis factor monoclonal antibody                                       
                     on cytokine levels in patients with sepsis,” Critical Care Medicine, Vol. 21, No. 3,                                          
                     pp. 318-327 (March 1993).                                                                                                     

                     Wispé et al. (Wispé), “Tumor Necrosis Factor-Alpha inhibits Expression of                                                     
                     Pulmonary Surfactant Protein,” Journal of Clinical Investigation, Vol. 86, pp. 1954-                                          
                     1960 (December 1990.)                                                                                                         



                                                                                                                                                   
                              2 During a telephone interview between the Examiner and Appellants’ representative on July                           
                     21, 1997, it was decided that the Examiner would add a new grounds of rejection for claims 17 and                             
                     19-21 since they have the same language as claim 18 which was found to be indefinite by the                                   
                     Examiner.  Appellants appear to have rejected the Examiner’s offer of withdrawing the final rejection                         
                     or canceling the claims by Examiner’s amendment and allowing the application as alternative                                   
                     courses of action.                                                                                                            
                              3 There seems to be some confusion in Appellants’ Reply Brief (paper 23) as to which                                 
                     claims are pending in the application.  In section 3 of the Reply Brief, Appellants indicate that claim                       
                     18 is appealed and that claims 17-21 have been rejected for the same reasons as applied to claim                              
                     18.  Appellants state that claims 1, 2, 4-7, 9-11 and 13-36 are pending. Id., page 3.  In section 7,                          
                     Appellants also state that “[n]ew claims 37-41 are not under appeal.” Id., page 5.  These claims are                          
                     not under appeal because they are not pending in the application.  It appears that Appellants’ Reply                          
                     Brief was accompanied by an amendment filed December 2, 1997, in which new claims 37-41 were                                  
                     presented.  In a letter mailed February 2, 1998 (paper 24), Appellants were advised that the Reply                            
                     Brief was entered and noted but that the amendment filed December 2, 1997, was not entered                                    
                                                                        2                                                                          







Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007